Role of surgical resection in adult urological soft tissue sarcoma: 25-Year experience by Izumi Kouji et al.
Role of surgical resection in adult urological
soft tissue sarcoma: 25-Year experience
著者 Izumi Kouji, Mizokami Atsushi, Sugimoto
Kazuhiro, Narimoto Kazutaka, Miyagi Tohru,
Maeda Yuji, Kitagawa Yasuhide, Kadono











Role of Surgical Resection in Adult Urological Soft Tissue Sarcoma: 25-year 
Experience 
 
Kouji Izumi, Atsushi Mizokami, Kazuhiro Sugimoto, Kazutaka Narimoto, Tohru 
Miyagi, Yuji Maeda, Yasuhide Kitagawa, Yoshifumi Kadono, Hiroyuki Konaka, Mikio 
Namiki 
 
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate 
School of Medical Science, Kanazawa, Japan 
 
Short title: Adult urological soft tissue sarcoma 
 
Corresponding author: Address correspondence to Kouji Izumi, M. D., Department of 
Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of 
Medical Science, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan. Telephone: 
+81-76-265-2393, Fax: +81-76-222-6726, E-mail:azuizu2003@yahoo.co.jp
 




Introduction: As adult urological soft tissue sarcomas are rare, there have been few 
recent large-scale studies of these tumors. This report describes a single institutional 
experience of adult urological soft tissue sarcomas over 25 years. 
 
Materials and Methods: The study population consisted of 25 adult patients with 
histologically diagnosed soft tissue sarcoma arising in the urinary tract, male genital 
system, or retroperitoneum between January 1983 and July 2008. The study endpoint 
was overall survival. The crude probability of survival was estimated using the 
Kaplan-Meier method. Univariate and multivariate analysis of differences between 
patient groups was performed with the log rank test and Cox proportional hazards 
model. 
 
Results: Overall survival rate at 5 years was 54.2%. On univariate analysis, unfavorable 
prognostic variables for overall survival were presence of metastasis at diagnosis 
(P=0.0005), absence of surgical resection (P=0.0003), histological subtype of 
rhabdomyosarcoma (P=0.0068), and primary organs other than retroperitoneum 
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(P=0.0410). On multivariate analysis, absence of surgical resection remained a 
significant predictor of unfavorable prognosis (HR 2.67, 95% CI 1.03 to 7.76, P=0.044). 
 
Conclusions: Surgical resection, regardless of status of surgical resection margin, 
contributed to a favorable prognosis in adult patients with locally advanced or 




Soft tissue sarcomas (STS) constitute a heterogeneous group of rare solid tumors of 
mesenchymal cell origin with distinct clinical and pathological features. The annual 
incidence of STS in the USA for 2007 was estimated to be about 10,390 cases, with an 
overall mortality rate of approximately 3,680 cases per year [1]. Less than 5% of STS 
arise from the genitourinary tract, accounting for only 1 to 2% of all malignant 
genitourinary tumors [2]. Due to the rarity of urological STS, clinical research is limited 
and there have been few recent large, institution-based studies. The largest series with 
131 cases was collected at the Memorial Sloan-Kettering Cancer Center (MSKCC) 
between July 1977 and July 2003 [3]. In their study, tumor size and absence of 
metastasis at diagnosis remained significant predictors of disease-specific survival on 
multivariate analysis. In the present study, a series of 25 adult urological STS at our 
institution were reviewed and their prognostic factors were analyzed. This is the largest 
such series reported to date in Japan. 
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Materials and Methods 
 
Patients 
Patients histologically diagnosed as having STS arising in organs treated by urologists, 
such as the urinary tract, male genital system, or retroperitoneum, from January 1983 to 
July 2008 were included in this study. All patients were 15 years or older at diagnosis. 
Variables analyzed were patient age, sex, tumor size, and histological subtype, primary 
organ, metastasis at diagnosis, and status of the surgical resection margins. 
Postoperative adjuvant therapies and treatment after recurrences were also described. 
Although 2 patients were operated with palliative intent to improve local symptoms, we 
basically intended to resect tumors completely with curative intent at operation. 
However, as a result, complete resection was not accomplished in all cases. Surgical 
resection margins were documented by both the surgeon and the pathologist in 
evaluating resected specimens. In accordance with the National Comprehensive Cancer 
Network [4], the status of surgical resection margins was defined as follows: R0 
resection, no residual microscopic disease; R1 resection, microscopic residual disease; 
and R2 resection, gross residual disease. Local recurrence or metastasis was defined as 
the first recurrence of disease at the primary tumor site or distant site detected by 
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radiographic modality, such as computed tomography. 
 
Statistical analysis 
The date of surgery or biopsy was used as the start of observation. Overall survival was 
the study endpoint. The crude probability of survival was estimated using the 
Kaplan-Meier method. Univariate analysis of differences between patient groups was 
performed with the log rank test. Multivariate analysis of variables that were significant 
on univariate analysis was analyzed with the Cox proportional hazards model. Statistical 





Patient characteristics are shown in table 1. A total of 25 cases were included in this 
analysis. The most common site was the retroperitoneum (14 cases, 56%), followed by 
bladder, kidney, and paratesticular tumors each with 3 cases (12%) and the prostate with 
2 cases (8%). The most common histological subtype was rhabdomyosarcoma (7 cases, 
28%), followed by liposarcoma with 5 cases (20%), malignant fibrous histiocytoma 
(MFH) and leiomyosarcoma each with 4 cases (16%). The remaining five cases had 
other histological subtypes (20%), which included angiosarcoma, malignant 
hemangiopericytoma, malignant schwannoma, malignant solitary fibrous tumor, and 
unclassified sarcoma. Of the 25 patients, 5 (20%) presented with metastatic disease and 
21 (84%) underwent surgical resection. Of these 21 patients, 19 (90%) underwent 
surgical resection with curative intent and 2 (10%) underwent surgical resection with 
palliative intent (R2 resection). Of the 19 patients who underwent surgical resection 
with curative intent, 8 (42%) underwent complete resection (R0 resection), 6 (32%) 
underwent incomplete resection with microscopically residual disease (R1 resection) 
and 2 (11%) underwent incomplete resection with gross residual disease (R2 resection). 
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Surgical resection margin status was not determined in 3 patients (16%) (Rx resection). 
All 11 patients of R0 and Rx resection did not undergo postoperative adjuvant therapy. 
Four of 8 R0 resection patients had recurrence and 3 patients underwent treatment after 
recurrence as follows; re-operation of tumor resection, chemotherapy (CT), 
embolization followed by radiofrequency ablation. All 3 Rx patients had recurrence 
and underwent treatment after recurrence as follows; radiation therapy (RT), CT with 
RT (2 patients). Two of 6 R1 resection patients underwent postoperative adjuvant 
therapy of CT and CT with RT. Five of 6 R1 resection patients, including 2 patients who 
underwent postoperative adjuvant therapy, had recurrence and underwent treatment after 
recurrence as follows; CT with RT, immunotherapy, re-operation of tumor resection (2 
patients), re-operation of tumor resection followed by CT. One of 4 R2 resection 
patients underwent CT with RT after surgical resection. Median recurrence interval of 
R0, R1 and Rx resection was 41.5 months (range 14-69 months), 4 months (range 2-53 
months) and 41 months (range 7-77 months), respectively. Two of R0 resection patients 
had distant recurrence sites, one had multiple bone metastases and the other had liver 
and thighbone metastases. Other patients had local recurrences. Four of 10 local 
recurrence patients underwent re-operation with curative intent and the number of the 
patient of R0, R1 and Rx was 2, 1 and 1, respectively. All of 4 patients who did not 
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undergo surgical resection underwent CT, RT (2 patients), and CT with RT. 
 
Overall survival 
At the end of the study follow-up period, 15 of the 25 patients were alive. Overall 
survival rate at 5 years was 54.2% and median survival time was 63 months (fig. 1a). 
Overall survival rate of inoperable, R2 resection, and recurrent cases at 5 years was 
28.1% and median survival time was 25 months (fig. 1b). The distribution of 25 STS 
according to histological characteristics is shown in table 2. On univariate analysis, 
unfavorable prognostic variables for overall survival were presence of metastasis at 
diagnosis (P=0.0005; overall survival at 5 years, 0% vs. 73.2%), absence of surgical 
resection (P=0.0003; overall survival at 5 years, 0% vs. 66.8%), histological subtype of 
rhabdomyosarcoma (P=0.0068; overall survival at 5 years, 21.4% vs. 67.7%), and 
primary organs other than retroperitoneum (P=0.0410; overall survival at 5 years, 
38.2% vs. 69.3%) (fig. 1c–f). There were no significant differences in survival 
according to age (P=0.1687), sex (P=0.1722), tumor size (largest dimension classified 
by less than 10 cm vs. greater than 10 cm, less than 15 cm vs. greater than 15 cm, and 
less than 20 cm vs. greater than 20 cm; P=0.1464, 0.4503, and 0.5958, respectively). 
There were also no significant differences between R0 and R1 resection (P=0.2385), or 
 10
between R0 and R1+2 resection (P=0.0722). There were no significant differences in 
survival according to whether undergoing CT or not (P=0.7084) and undergoing RT or 
not (P=0.3721). On multivariate analysis, absence of surgical resection remained a 





As adult urological STS is very rare, clinical research regarding this disease is difficult. 
To our knowledge, this is the first case series study of adult urological STS performed in 
Japan. There have been 3 previous clinical studies of adult urological STS. Mondaini et 
al. reported a series including 22 adult patients with genitourinary sarcomas of different 
histological types who were identified and reviewed in a multicenter study performed in 
8 different hospitals in Tuscany, central Italy [5]. The MSKCC group reported two 
consecutive series, one including 43 patients treated between 1982 and 1989 [6] and 
another including 131 patients between performed between 1977 and 2003. The latter 
study extended the former with prolonged follow-up, and allowed the use of multiple 
variables for determining local recurrence-free and disease-specific survival [3]. Less 
than 5% of STS arise in the genitourinary tract and only 15% of STS arise within the 
retroperitoneum [2,7]. All retroperitoneal STS are considered deep lesions with a 
generally poor prognosis [8,9]. 
Overall survival rate at 5 years was 54.2% and median survival time was 63 months. 
These results were consistent with those of the previous study by Coindre et al. in 
which the 5-year survival rate of STS was 50–60% [10]. On univariate analysis, the 
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presence of metastasis, rhabdomyosarcoma, primary organs other than the 
retroperitoneum, and absence of surgical resection were unfavorable prognostic 
variables for overall survival. The presence of metastasis and rhabdomyosarcoma were 
reported previously to be unfavorable prognostic variables [3]. Prognosis of 
genitourinary STS may be more unfavorable than that of retroperitoneal STS. On 
multivariate analysis, the absence of surgical resection remained as an unfavorable 
prognostic variable for overall survival. Lewis et al. reported the presence of 
unresectable disease and incomplete surgical resection as the most significant factors 
predictive of disease-specific death [11]. In a study by van Dalen et al. in 143 patients 
treated in the Netherlands, complete tumor resection was correlated with better overall 
survival on multivariate analysis [12]. However, Dotan et al. reported that complete 
resection was not a significant factor predictive of disease-specific survival on 
univariate and multivariate analysis in 102 patients with primary tumors only [3]. 
Interestingly, in the present study there were no significant differences between R0 and 
R1 resection or between R0 and R1+2 resection. These results suggest that any type of 
surgical resection can provide the best chance of survival in patients presenting with 
primary disease or with primary and metastatic disease. 
Size of STS is an important prognostic variable. According to the American Joint 
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Committee on Cancer staging criteria for STS, sarcomas have classically been stratified 
into two groups on the basis of size: T1 lesions are 5 cm or smaller, and T2 lesions are 
larger than 5 cm [13]. In the present study, all sarcomas were greater than 5 cm in the 
largest dimension. This may have been because STS arising from retroperitoneum can 
achieve a large size due to the flexibility of the retroperitoneum and the large volume of 
space available for organ displacement. There were no significant differences in size of 
tumors in the present study. However, Ramanathan et al. suggested that further 
stratification of tumors larger than 5 cm would provide more accurate prognostic 
information. When 316 patients with STS were grouped into four subgroups on the basis 
of tumor size (less than 5 cm, 5 to less than 10 cm, 10 to 15 cm, and greater than 15 cm), 
each subgroup had a different prognosis, as shown by the 5-year survival rates of 84%, 
70%, 50%, and 33%, respectively [14]. R0 resection may be an important prognostic 
factor in the early phase of STS with small tumors of less than 5 cm. However, any type 
of surgical resection can be a prognostic factor in the advanced phase with large tumors 
greater than 5 cm or with metastases as in the present cases. 
As to metastatic or advanced STS except for specific types of sarcomas such as 
gastrointestinal stromal tumor, the effect of CT or RT is not established. In the present 
study, R1 and R2 resection patients could be comparable with R0 resection patients in 
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respect to postoperative adjuvant therapy, because only 2 R1 resection patients 
underwent postoperative adjuvant therapy of CT or CT with RT. It may be improper to 
assess the efficacy of CT and RT, because the sample size was small and various 
treatments were metachronously performed. However, we tried to analyze the efficacy 
of CT and RT on univariate analysis about inoperable, R2 resection, and recurrent cases. 
We could not clarify that surgical resection improved the efficacy of CT and RT. 
The present study had a number of limitations. Small sample size may have prevented 
determination of the precise statistical significance. Histological grade was not 
considered as a prognostic variable in the present study because it was not clear in some 
older specimens. Moreover, all patients were Japanese, so the distribution of STS 
according to histological subtype or primary organ may differ in patients from other 
ethnic backgrounds. 
Finally, this study provided evidence that surgical resection, regardless of the status of 
the surgical margins, may contribute to a favorable prognosis in adult patients with 
urological STS. Larger prospective studies with longer follow-up periods are needed to 




In the present study, although sample size was small, it was confirmed that surgical 
resection, regardless of status of surgical margins, may contribute to a favorable 
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Fig. 1. Kaplan-Meier analysis of overall survival (a) in overall cases, (b) in inoperable, 
palliatively resected or recurrent cases, (c) according to presence vs. absence of 
metastasis at diagnosis, (d) according to presence vs. absence of surgical resection, (e) 
according to histological subtype of rhabdomyosarcoma vs. other, and (f) according 
primary organ of retroperitoneum vs. other. 
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Table 1 Characteristics in patients with urological STS 
Variable n 
No. patients 25 
Median age at diagnosis (range) 54 (16-77) 
No. men/women (%) 21 (84) / 4 (16) 
Median months followup (range) 25 (1-182) 
No. primary organ (%)  
 Retroperitoneum 14 (56) 
 Bladder 3 (12) 
 Kidney 3 (12) 
 Paratesticular 3 (12) 
 Prostate 2 (8) 
No. histological subtype (%)  
 Rhabdomyosarcoma 7 (28) 
 Liposarcoma 5 (20) 
 MFH 4 (16) 
 Leiomyosarcoma 4 (16) 
 Other 5 (20) 
No. metastasis at diagnosis (%)  
 Yes 5 (20) 
 No 20 (80) 
No. underwent resection (%)  
 Yes 21 (84) 
 No 4 (16) 
No. complete resection (%)  
 Yes (negative margin, R0 resection) 8 (38) 
 No positive margin, R1 resection 6 (29) 
  gross residue, R2 resection 4 (19) 
 unknown, Rx resection 3 (14) 
No. tumor size (largest dimension) (%)  
 < 10 cm 8 (32) 
 10-15 cm 5 (20) 
 15-20 cm 4 (16) 
 > 20 cm 4 (16) 
 21
 unknown 4 (20) 
No. adjuvant therapy (%)  
 Chemotherapy 9 (36) 
 Radiotherapy 9 (36) 
 Other or none 7 (28) 
No. last follow-up status (%)  
 No evidence of disease 5 (20) 
 Disease 10 (40) 
 Dead of disease 10 (40) 




Table 2 Distribution of 25 urological sarcomas according to histological characteristics 
Primary organ 
Histological subtype n Met. Res.
Retro. Bladder Kidney Parates. Prostate
Rhabdomyosarcoma 7 3 5 1 1 2 1 2 
Liposarcoma 5  5 4   1  
MFH 4 1 3 3 1    
Leiomyosarcoma 4  4 3  1   
Other 5 1 4 3 1  1  
Total 25 5 21 14 3 3 3 2 
Met., metastasis; Res., resection; Retro., retroperitoneum; Parates., paratesticular; MFH, 




Table 3 Multivariate analysis of variables and overall survival in 25 patients 
Variables HR (95% CI) P value 
Primary organ (other vs retro.) 1.32 0.562 
Histological subtype (rhabdo. vs other) 1.78 0.154 
Metastasis at diagnosis (yes vs no) 1.41 0.374 
Underwent resection (no vs yes) 2.67 (1.03-7.76) 0.044 
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No. metastasis at diagnosis (%)
Yes
No
No. underwent resection (%)
Yes
No
No. complete resection (%)
Yes (negative margin, R0 resection)
positive margin, R1 resection
palliative, R2 resection
unknown





MFH, malignant fibrous histiocytoma
> 20 cm
unknown
No. last follow-up status (%)
No evidence of disease
Disease
Retro. Bladder Kidney Parates.Prostate
7 3 5 1 1 2 1 2
Liposarcoma 5 5 4 1
4 1 3 3 1
4 4 3 1
Other 5 1 4 3 1 1
Total 25 5 21 14 3 3 3 2
Met., metastasis; Res., resection; Retro., retroperitoneum; Parates.,
paratesticular; MFH, malignant fibrous histiocytoma
Leiomyosarcoma












Retro., retroperitoneum; Rhabdo., rhabdomyosarcoma
Table 3  Multivariate analysis of variables and overall survival in 25 patients
Primary organ (other vs retro.)





Metastasis at diagnosis (yes vs no)
Underwent resection (no vs yes)
